Small Cell Lung Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

Lung Cancer (4108)

Non Small Cell Lung Cancer (3691)

Lung Cancer (4108)

Non Small Cell Lung Cancer (3691)

›

No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	topotecan Sensitive: A1 - Approval topotecan Sensitive : A1	topotecan Sensitive: A1 - Approval topotecan Sensitive : A1
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	lurbinectedin Sensitive: A1 - Approval lurbinectedin Sensitive : A1	lurbinectedin Sensitive: A1 - Approval lurbinectedin Sensitive : A1
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	serplulimab Sensitive: A1 - Approval serplulimab Sensitive : A1	serplulimab Sensitive: A1 - Approval serplulimab Sensitive : A1
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	etoposide oral Sensitive: A2 - Guideline etoposide oral Sensitive : A2	etoposide oral Sensitive: A2 - Guideline etoposide oral Sensitive : A2
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	vinorelbine tartrate Sensitive: A2 - Guideline vinorelbine tartrate Sensitive : A2	vinorelbine tartrate Sensitive: A2 - Guideline vinorelbine tartrate Sensitive : A2
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	irinotecan Sensitive: A2 - Guideline irinotecan Sensitive : A2	irinotecan Sensitive: A2 - Guideline irinotecan Sensitive : A2
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	bevacizumab Resistant: A2 - Guideline bevacizumab Resistant : A2	bevacizumab Resistant: A2 - Guideline bevacizumab Resistant : A2
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	carboplatin + etoposide IV Sensitive: A2 - Guideline carboplatin + etoposide IV Sensitive : A2	carboplatin + etoposide IV Sensitive: A2 - Guideline carboplatin + etoposide IV Sensitive : A2
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	cisplatin + etoposide IV Sensitive: A2 - Guideline cisplatin + etoposide IV Sensitive : A2	cisplatin + etoposide IV Sensitive: A2 - Guideline cisplatin + etoposide IV Sensitive : A2
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	carboplatin + gemcitabine Sensitive: A2 - Guideline carboplatin + gemcitabine Sensitive : A2	carboplatin + gemcitabine Sensitive: A2 - Guideline carboplatin + gemcitabine Sensitive : A2
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	cisplatin + topotecan Sensitive: A2 - Guideline cisplatin + topotecan Sensitive : A2	cisplatin + topotecan Sensitive: A2 - Guideline cisplatin + topotecan Sensitive : A2
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	cisplatin + irinotecan Sensitive: A2 - Guideline cisplatin + irinotecan Sensitive : A2	cisplatin + irinotecan Sensitive: A2 - Guideline cisplatin + irinotecan Sensitive : A2
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	trilaciclib Sensitive: B - Late Trials trilaciclib Sensitive : B	trilaciclib Sensitive: B - Late Trials trilaciclib Sensitive : B
PD-L1 expression	Small Cell Lung Cancer	PD-L1 expression	Small Cell Lung Cancer	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	CS 2164 Sensitive: B - Late Trials CS 2164 Sensitive : B	CS 2164 Sensitive: B - Late Trials CS 2164 Sensitive : B
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	nanoliposomal irinotecan Sensitive: B - Late Trials nanoliposomal irinotecan Sensitive : B	nanoliposomal irinotecan Sensitive: B - Late Trials nanoliposomal irinotecan Sensitive : B
DLL3 overexpression	Small Cell Lung Cancer	DLL3 overexpression	Small Cell Lung Cancer	rovalpituzumab tesirine Sensitive: B - Late Trials rovalpituzumab tesirine Sensitive : B	rovalpituzumab tesirine Sensitive: B - Late Trials rovalpituzumab tesirine Sensitive : B
TMB-H	Small Cell Lung Cancer	TMB-H	Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: B - Late Trials nivolumab + ipilimumab Sensitive : B	nivolumab + ipilimumab Sensitive: B - Late Trials nivolumab + ipilimumab Sensitive : B
TMB-H	Small Cell Lung Cancer	TMB-H	Small Cell Lung Cancer	nivolumab Sensitive: B - Late Trials nivolumab Sensitive : B	nivolumab Sensitive: B - Late Trials nivolumab Sensitive : B
HLA-DQB1*03:01	Small Cell Lung Cancer	HLA-DQB1*03:01	Small Cell Lung Cancer	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B

Small Cell Lung Cancer

Associations(155)

Associations
(155)